NCT02316002View on ClinicalTrials.gov

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 21, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

December 31, 2022

Conditions
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Pembrolizumab

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02316002 - Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter